Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis
CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14...
Saved in:
Published in | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 11; no. 5; pp. 234 - 238 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
01.10.2005
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease. |
---|---|
AbstractList | CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease. CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4 h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease. CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4 h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease.CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified a previously unknown form of soluble CD14, named soluble CD14 subtype (sCD14-ST), that is increased in patients with sepsis. To measure sCD14-ST concentrations in plasma, we prepared anti-sCD14-ST antibodies and developed an enzyme immunoassay (EIA) for this soluble form of CD14. With this assay, quantitative measurements are available within 4 h, and we compared the levels of sCD14-ST in plasma from normal subjects (healthy controls), patients with systemic inflammatory response syndrome (SIRS), and sepsis patients. The level of sCD14-ST in subjects with sepsis was much higher than the levels in subjects with SIRS and the healthy controls. Additionally, when a subject's sCD14-ST level was used as a diagnostic marker for sepsis, the area under the receiver operating characteristic (ROC) curve was 0.817, thereby demonstrating that elevated sCD14-ST levels were a better marker for sepsis than the other molecular markers we tested. sCD14-ST levels also correlated with procalcitonin (PCT) levels and with sequential organ failure assessment (SOFA) scores. Finally, changes in sCD14-ST concentration correlated with the severity of sepsis. Taken together, these results indicate that sCD14-ST is a useful marker for the rapid diagnosis of sepsis and for monitoring the severity of the disease. |
Author | Sato, Nobuhiro Furusako, Shoji Endo, Shigeatsu Imai, Satoko Miyata, Michiko Suzuki, Yasushi Takahashi, Gaku Yaegashi, Yasunori Shirakawa, Kamon Kojika, Masahiro |
Author_xml | – sequence: 1 givenname: Yasunori surname: Yaegashi fullname: Yaegashi, Yasunori – sequence: 2 givenname: Nobuhiro surname: Sato fullname: Sato, Nobuhiro – sequence: 3 givenname: Yasushi surname: Suzuki fullname: Suzuki, Yasushi – sequence: 4 givenname: Masahiro surname: Kojika fullname: Kojika, Masahiro – sequence: 5 givenname: Satoko surname: Imai fullname: Imai, Satoko – sequence: 6 givenname: Gaku surname: Takahashi fullname: Takahashi, Gaku – sequence: 7 givenname: Michiko surname: Miyata fullname: Miyata, Michiko – sequence: 8 givenname: Shigeatsu surname: Endo fullname: Endo, Shigeatsu email: sendo@iwate-med.ac.jp – sequence: 9 givenname: Kamon surname: Shirakawa fullname: Shirakawa, Kamon – sequence: 10 givenname: Shoji surname: Furusako fullname: Furusako, Shoji |
BackLink | https://cir.nii.ac.jp/crid/1571135650252594048$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/16258819$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1v1DAQxS1URD_gD-CCfEDcAjOJPxJxQktpkVbiAhI3y3HGkqk3Weyk1f73eEnh0EN7sefwe_M0752zk3EaibHXCO8RQH_ICChVBSArEACVeMbOUDS60rqFkzI3Aqumxp-n7DznXwCoZdu-YKeo6jJgd8a2l7c2LnYO08gnzy0f6S4eeBhonIMPNPA8xaWPxDefUfC89PNhT9zmgu5suqHE_ZR4pn0O-SV77m3M9Or-v2A_vlx-31xX229XXzeftpUTSs2VgM75ppFWu96L1grpfYe2Jemgt53uEGzdS98qV87shVBoUdbCOtG3Xvnmgr1b9-7T9HuhPJtdyI5itCNNSzaq1QJBdk-CqGvsUEMB39yDS7-jwexTKNcdzL-gCqBXwKUp50TeuDD_jW1ONkSDYI6VmLUSUyoxx0qMKEp8oPy__BHN21UzhlCMji9KjdhIJaGWtewEiLZgH1eMSti3gZLJLtDoaAiJ3GyGKTxq0j1Qu1isnI03dHhC-wd0i7uW |
CitedBy_id | crossref_primary_10_1038_s41372_024_01973_9 crossref_primary_10_1007_s00508_015_0719_5 crossref_primary_10_4103_AZMJ_AZMJ_122_19 crossref_primary_10_1093_tropej_fmac001 crossref_primary_10_1016_j_dld_2019_05_025 crossref_primary_10_3390_biomedicines13030701 crossref_primary_10_1007_s13341_013_0347_5 crossref_primary_10_3390_diagnostics15020217 crossref_primary_10_1186_s13613_016_0160_6 crossref_primary_10_1016_j_cca_2016_11_036 crossref_primary_10_4103_jwas_jwas_132_24 crossref_primary_10_1186_s13613_015_0089_1 crossref_primary_10_5312_wjo_v14_i7_547 crossref_primary_10_23736_S0375_9393_20_14169_5 crossref_primary_10_1016_j_ccc_2019_08_001 crossref_primary_10_3390_diagnostics11010060 crossref_primary_10_5937_afmnai41_46406 crossref_primary_10_1186_s40560_019_0374_4 crossref_primary_10_1016_j_transproceed_2013_07_021 crossref_primary_10_1186_s13054_015_1032_4 crossref_primary_10_1515_JLM_2008_030 crossref_primary_10_18527_2500_2236_2023_10_1_70_90 crossref_primary_10_1371_journal_pone_0129159 crossref_primary_10_1186_cc12847 crossref_primary_10_1016_j_pepo_2013_06_011 crossref_primary_10_1039_C8LC01102H crossref_primary_10_1016_j_rmed_2014_05_005 crossref_primary_10_1016_j_jiac_2016_04_002 crossref_primary_10_33878_2073_7556_2019_18_3_105_118 crossref_primary_10_3109_14767058_2012_717462 crossref_primary_10_5761_atcs_ra_15_00187 crossref_primary_10_1016_j_clinbiochem_2019_12_007 crossref_primary_10_1016_j_ijid_2020_10_030 crossref_primary_10_3390_biomedicines10102332 crossref_primary_10_1371_journal_pone_0053692 crossref_primary_10_1515_tjb_2018_0220 crossref_primary_10_1186_2110_5820_3_22 crossref_primary_10_1007_s00101_014_2347_2 crossref_primary_10_1080_00365513_2022_2031278 crossref_primary_10_1016_j_cca_2015_08_013 crossref_primary_10_1186_s12890_018_0740_3 crossref_primary_10_1177_0310057X1704500510 crossref_primary_10_2152_jmi_68_105 crossref_primary_10_1097_ALN_0000000000001522 crossref_primary_10_3389_fneur_2018_00058 crossref_primary_10_1515_jccm_2017_0001 crossref_primary_10_2147_IDR_S325635 crossref_primary_10_1097_MS9_0000000000001643 crossref_primary_10_33713_egetbd_950007 crossref_primary_10_1016_j_apjtb_2016_04_005 crossref_primary_10_1055_a_1303_5105 crossref_primary_10_37748_2686_9039_2022_3_2_1 crossref_primary_10_1001_jamapediatrics_2022_1647 crossref_primary_10_1186_s12879_023_08353_2 crossref_primary_10_23736_S0375_9393_20_13661_7 crossref_primary_10_1515_JLM_2008_030et crossref_primary_10_1017_S1466252322000019 crossref_primary_10_25016_2541_7487_2018_0_4_59_67 crossref_primary_10_1371_journal_pone_0146020 crossref_primary_10_3923_ajbmb_2023_49_60 crossref_primary_10_1097_MS9_0000000000000426 crossref_primary_10_1007_s10156_011_0254_x crossref_primary_10_1371_journal_pone_0133057 crossref_primary_10_1371_journal_pone_0175254 crossref_primary_10_1016_j_molimm_2018_06_006 crossref_primary_10_4155_ppa_13_3 crossref_primary_10_1016_j_cca_2016_06_030 crossref_primary_10_1016_j_ejccm_2017_02_001 crossref_primary_10_2169_internalmedicine_55_6524 crossref_primary_10_36488_cmac_2020_3_175_187 crossref_primary_10_3390_jfmk7040097 crossref_primary_10_3390_tropicalmed7110355 crossref_primary_10_3389_fneur_2024_1429354 crossref_primary_10_1016_j_biopha_2018_12_124 crossref_primary_10_1186_cc13700 crossref_primary_10_1016_j_burnso_2017_05_010 crossref_primary_10_1016_j_rbmo_2023_103622 crossref_primary_10_1016_j_jcrc_2014_06_014 crossref_primary_10_1155_2015_792572 crossref_primary_10_1007_s12026_018_8994_7 crossref_primary_10_1016_j_jiac_2020_11_013 crossref_primary_10_5005_jp_journals_10071_23741 crossref_primary_10_1097_SHK_0000000000001269 crossref_primary_10_1097_MD_0000000000002158 crossref_primary_10_1620_tjem_246_199 crossref_primary_10_1371_journal_pone_0273930 crossref_primary_10_1093_burnst_tkaa047 crossref_primary_10_21320_2500_2139_2019_12_4_461_467 crossref_primary_10_12688_hrbopenres_13633_1 crossref_primary_10_3393_ac_2022_00115_0016 crossref_primary_10_1007_s00005_016_0415_9 crossref_primary_10_1186_1471_2253_14_88 crossref_primary_10_1097_BRS_0000000000002376 crossref_primary_10_1248_bpb_29_1015 crossref_primary_10_1016_j_cca_2011_07_024 crossref_primary_10_1016_j_jiac_2013_07_005 crossref_primary_10_1097_CCE_0000000000000591 crossref_primary_10_1093_burnst_tkae080 crossref_primary_10_2144_btn_2020_0136 crossref_primary_10_1186_cc14053 crossref_primary_10_1002_jhbp_802 crossref_primary_10_1515_tjb_2018_0532 crossref_primary_10_1016_j_jiac_2018_10_015 crossref_primary_10_1007_s00540_012_1502_7 crossref_primary_10_1016_j_clineuro_2025_108767 crossref_primary_10_1186_s40560_017_0246_8 crossref_primary_10_51620_0869_2084_2022_67_8_471_475 crossref_primary_10_1016_j_burns_2013_08_024 crossref_primary_10_1186_s40635_021_00400_z crossref_primary_10_1213_ANE_0000000000003738 crossref_primary_10_1080_14787210_2019_1584037 crossref_primary_10_3390_jcm13195991 crossref_primary_10_1097_EJA_0000000000001243 crossref_primary_10_1186_s13052_016_0268_1 crossref_primary_10_1038_s41598_022_06613_w crossref_primary_10_7448_IAS_19_8_21487 crossref_primary_10_1111_febs_15552 crossref_primary_10_1007_s00101_017_0363_8 crossref_primary_10_3390_medicina58111504 crossref_primary_10_36290_vnl_2019_078 crossref_primary_10_1007_s12223_014_0346_y crossref_primary_10_1017_cts_2023_538 crossref_primary_10_4236_ajmb_2014_44019 crossref_primary_10_47429_lmo_2024_14_2_111 crossref_primary_10_1093_postmj_qgad132 crossref_primary_10_1186_cc13183 crossref_primary_10_1016_j_ejim_2017_09_030 crossref_primary_10_1186_s13054_023_04367_z crossref_primary_10_1186_s12865_020_00362_z crossref_primary_10_1186_cc13070 crossref_primary_10_1371_journal_pone_0143971 crossref_primary_10_1186_s12879_019_4316_5 crossref_primary_10_5847_wjem_j_issn_1920_8642_2014_01_002 crossref_primary_10_1038_s41598_022_22096_1 crossref_primary_10_1371_journal_pone_0215791 crossref_primary_10_1007_s00101_017_0396_z crossref_primary_10_1186_s40902_022_00353_7 crossref_primary_10_3390_jcm13237038 crossref_primary_10_1007_s00134_007_0626_y crossref_primary_10_5604_01_3001_0016_0233 crossref_primary_10_3389_fmed_2023_1126982 crossref_primary_10_3109_14767058_2014_942627 crossref_primary_10_1016_j_cca_2015_06_026 crossref_primary_10_1111_aas_14291 crossref_primary_10_1016_j_cca_2020_09_014 crossref_primary_10_1186_s41100_017_0113_z crossref_primary_10_3893_jjaam_23_27 crossref_primary_10_1016_j_clinbiochem_2014_04_014 crossref_primary_10_2217_bmm_2019_0183 crossref_primary_10_5493_wjem_v5_i2_50 crossref_primary_10_1136_bmjopen_2016_014305 crossref_primary_10_1016_j_jss_2022_04_072 crossref_primary_10_1016_j_clineuro_2019_105396 crossref_primary_10_1038_s41598_024_80686_7 crossref_primary_10_1080_14397595_2016_1246119 crossref_primary_10_1186_s12894_021_00906_4 crossref_primary_10_18527_2500_2236_2023_10_1_70_90_RU crossref_primary_10_3109_14767058_2011_601923 crossref_primary_10_1186_s12879_016_2116_8 crossref_primary_10_17116_labs2017627_14 crossref_primary_10_1111_j_1744_9987_2006_00340_x crossref_primary_10_1186_s10195_022_00644_9 crossref_primary_10_1016_j_cca_2017_12_045 crossref_primary_10_1097_MD_0000000000031895 crossref_primary_10_1186_s13054_024_05032_9 crossref_primary_10_1159_000538870 crossref_primary_10_1016_j_jss_2018_02_059 crossref_primary_10_1007_s00134_014_3514_2 crossref_primary_10_1038_s41598_023_48633_0 crossref_primary_10_12677_acm_2024_1441063 crossref_primary_10_1007_s10156_012_0435_2 crossref_primary_10_1186_s13104_024_06719_6 crossref_primary_10_3390_biomedicines9091076 crossref_primary_10_1016_j_cca_2015_07_025 crossref_primary_10_1515_CCLM_2011_145 crossref_primary_10_1016_j_jcrc_2017_04_008 crossref_primary_10_1038_s41598_024_66916_y crossref_primary_10_20408_jti_2023_0061 crossref_primary_10_1016_j_cca_2018_08_032 crossref_primary_10_3904_kjim_2023_558 crossref_primary_10_1016_j_ajem_2017_12_038 crossref_primary_10_17116_terarkh2015871184_91 crossref_primary_10_1007_s11882_007_0067_2 crossref_primary_10_1038_s41598_022_09926_y crossref_primary_10_1093_labmed_lmaa011 crossref_primary_10_3389_fmed_2024_1393843 crossref_primary_10_1016_j_cca_2014_11_012 crossref_primary_10_1080_14767058_2017_1366984 crossref_primary_10_1007_s12072_016_9753_2 crossref_primary_10_1007_s00414_012_0804_5 crossref_primary_10_1515_cclm_2013_0061 crossref_primary_10_1093_labmed_lmaa015 crossref_primary_10_3390_jpm15040125 crossref_primary_10_1016_j_jiac_2015_04_011 crossref_primary_10_1016_j_molimm_2016_11_012 crossref_primary_10_1371_journal_pone_0206089 crossref_primary_10_4266_acc_2022_00150 crossref_primary_10_1038_s41598_020_66121_7 crossref_primary_10_3390_children11030350 crossref_primary_10_1016_j_jinf_2015_09_007 crossref_primary_10_1093_labmed_lmz005 crossref_primary_10_1128_JCM_03052_14 crossref_primary_10_1016_j_forsciint_2019_03_034 crossref_primary_10_1016_j_ijid_2020_03_057 crossref_primary_10_1016_j_cca_2019_09_012 |
Cites_doi | 10.4049/jimmunol.147.5.1567 10.1093/nar/16.9.4173 10.1097/00003246-199206000-00025 10.1126/science.1698311 10.1016/0022-1759(92)90289-6 10.1051/vetres:2003006 10.1007/s00134-004-2210-z 10.1016/0140-6736(93)90277-N 10.1097/00003246-200008000-00019 10.1093/infdis/171.3.639 10.1182/blood.V92.6.2084.418k26_2084_2092 10.1164/ajrccm.155.3.9117029 10.1111/j.1365-2249.1994.tb06222.x 10.1093/infdis/173.3.661 10.1002/eji.1830250244 |
ContentType | Journal Article |
Copyright | 2005 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases |
Copyright_xml | – notice: 2005 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases |
DBID | RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL C1K 7X8 |
DOI | 10.1007/s10156-005-0400-4 |
DatabaseName | CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Bacteriology Abstracts (Microbiology B) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1437-7780 |
EndPage | 238 |
ExternalDocumentID | 16258819 10_1007_s10156_005_0400_4 10016776293 S1341321X05709764 |
Genre | Evaluation Studies Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --M -Y2 -~C .1- .55 .86 .FO .~1 0R~ 0VY 1N0 1P~ 1SB 1~. 2.D 28- 29K 2JY 2P1 2VQ 2~H 30V 4.4 408 409 40D 457 4G. 53G 5GY 5QI 5VS 67Z 6NX 7-5 8P~ 8TC 8UJ 95. 95~ AAAJQ AAEDT AAEDW AAIAL AAIKJ AAKOC AALRI AANXM AAOAW AAQFI AARHV AATTM AAXKI AAXUO AAYWO AAYZH ABFSG ABJNI ABMAC ABMNI ABMZM ABQSL ABXDB ACDAQ ACGFS ACIEU ACOMO ACRLP ACSTC ACVFH ADBBV ADCNI ADEZE ADHKG ADIMF ADKPE ADQRH ADRFC ADVLN AEBSH AEFIE AEIPS AEKER AENEX AEUPX AEVXI AEZWR AFBBN AFEXP AFHIU AFLOW AFPUW AFRHN AFTJW AFWTZ AFXIZ AGCQF AGGDS AGHFR AGJBK AGQPQ AGUBO AHBYD AHKAY AHSBF AHWEU AIEXJ AIGII AIIUN AIKHN AITUG AIXLP AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BA0 BBWZM BGNMA BKOJK BLXMC BNPGV CAG CJTIS COF CS3 CSCUP D-I DL5 EBS EFJIC EFKBS EJD EMOBN EN4 F5P FDB FEDTE FIRID FYGXN GBLVA GQ8 GXS H13 HF~ HG5 HG6 HMJXF HVGLF HZ~ I09 IHE IXC IXE IZIGR IZQ I~X KDC KOM KOW KPH LAS M41 M4Y MA- MO0 N2Q N9A NB0 NDZJH NU0 O9- O93 O9G O9I OAM OAUVE OC~ P-8 P-9 P19 P2P P9S PC. PT5 QOK QOS R4E R89 R9I RNI ROL RPX RRX RSV RZK S1Z S26 S27 S28 S37 S3B SDE SDH SDM SMD SOJ SPCBC SSH SSZ SV3 T13 T16 T5K TSK TSV TT1 TUC U2A VC2 WJK WK8 X7M Z45 Z5R ~A9 ~EX ~G- -5E -5G -BR 0SF AACTN AAIAV ABLVK ABTEG ABYKQ ADINQ AFKWA AFNRJ AHPSJ AJBFU AJOXV AMFUW EFLBG GQ6 NCXOZ RIG SSI SZN Z7U Z82 Z87 Z8O Z8V Z91 AFCTW AGRNS RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL C1K 7X8 |
ID | FETCH-LOGICAL-c466t-409cf335a7cbf48a45ff91a8e5c0ba97910a2b5f86c100b4461a1524ac4b8f6f3 |
IEDL.DBID | AIKHN |
ISSN | 1341-321X |
IngestDate | Fri Jul 11 05:07:24 EDT 2025 Mon Jul 21 09:46:11 EDT 2025 Wed Feb 19 02:43:24 EST 2025 Thu Apr 24 23:03:44 EDT 2025 Tue Jul 01 02:23:16 EDT 2025 Thu Jun 26 23:09:38 EDT 2025 Fri Feb 23 02:38:58 EST 2024 Tue Aug 26 16:59:28 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | SIRS Sepsis CD14 Diagnosis EIA |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c466t-409cf335a7cbf48a45ff91a8e5c0ba97910a2b5f86c100b4461a1524ac4b8f6f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 |
ORCID | 0000-0002-7296-8892 |
PMID | 16258819 |
PQID | 17219170 |
PQPubID | 23462 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_68741059 proquest_miscellaneous_17219170 pubmed_primary_16258819 crossref_citationtrail_10_1007_s10156_005_0400_4 crossref_primary_10_1007_s10156_005_0400_4 nii_cinii_1571135650252594048 elsevier_sciencedirect_doi_10_1007_s10156_005_0400_4 elsevier_clinicalkey_doi_10_1007_s10156_005_0400_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2005-Oct |
PublicationDateYYYYMMDD | 2005-10-01 |
PublicationDate_xml | – month: 10 year: 2005 text: 2005-Oct |
PublicationDecade | 2000 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
PublicationTitleAlternate | J. Infect. Chemother |
PublicationTitle_FL | J. Infect. Chemother |
PublicationYear | 2005 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Dellinger, Carlet, Masur, Gerlach, Calandra, Cohen (bib0080) 2004; 30 Lee, Paape, Zhao (bib0050) 2003; 34 Golenbock, Bach, Lichenstein, Juan, Tadavarthy, Moldow (bib0015) 1995; 125 Landmann, Zimmerli, Sansano, Link, Hahn, Glauser (bib0025) 1995; 171 Landmann, Reber, Sansano, Zimmerli (bib0055) 1996; 173 Endo, Inada, Kasai, Takakuwa, Nakae, Kikuchi (bib0030) 1994; 84 Martin, Rubenfeld, Ruzinski, Goodman, Steinberg, Leturcq (bib0040) 1997; 155 Wright, Ramos, Tobias, Ulevitch, Mathison (bib0010) 1990; 249 Grunwald, Krüger, Westermann, Lukowsky, Ehlers, Shütt (bib0020) 1992; 155 Lien, Aukrust, Sundan, Muller, Froland, Espevik (bib0035) 1998; 92 Bazil, Strominger (bib0075) 1991; 147 Oliver, Hartmut, Michael, Andreas, Wilfried, Jörg (bib0085) 2000; 28 Nockher, Wigarnd, Schoeppe, Scherberich (bib0045) 1994; 96 Assicot, Gendrel, Carsin, Raymond, Guilbaud, Bohuon (bib0065) 1993; 341 Ferrero, Goyert (bib0005) 1988; 16 (bib0060) 1992; 20 Bufler, Stieger, Schuchmann, Hess, Krüger, Stelter (bib0070) 1995; 25 Holzheimer, Capel, Cavaillon, Cainzos, Frileux, Haupt (bib0090) 2000; 5 Lien (10.1007/s10156-005-0400-4_bib0035) 1998; 92 Lee (10.1007/s10156-005-0400-4_bib0050) 2003; 34 Ferrero (10.1007/s10156-005-0400-4_bib0005) 1988; 16 Bufler (10.1007/s10156-005-0400-4_bib0070) 1995; 25 Oliver (10.1007/s10156-005-0400-4_bib0085) 2000; 28 Dellinger (10.1007/s10156-005-0400-4_bib0080) 2004; 30 Endo (10.1007/s10156-005-0400-4_bib0030) 1994; 84 Martin (10.1007/s10156-005-0400-4_bib0040) 1997; 155 Assicot (10.1007/s10156-005-0400-4_bib0065) 1993; 341 (10.1007/s10156-005-0400-4_bib0060) 1992; 20 Wright (10.1007/s10156-005-0400-4_bib0010) 1990; 249 Grunwald (10.1007/s10156-005-0400-4_bib0020) 1992; 155 Bazil (10.1007/s10156-005-0400-4_bib0075) 1991; 147 Golenbock (10.1007/s10156-005-0400-4_bib0015) 1995; 125 Landmann (10.1007/s10156-005-0400-4_bib0025) 1995; 171 Holzheimer (10.1007/s10156-005-0400-4_bib0090) 2000; 5 Nockher (10.1007/s10156-005-0400-4_bib0045) 1994; 96 Landmann (10.1007/s10156-005-0400-4_bib0055) 1996; 173 |
References_xml | – volume: 30 start-page: 536 year: 2004 end-page: 555 ident: bib0080 article-title: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock publication-title: Intensive Care Med – volume: 125 start-page: 662 year: 1995 end-page: 671 ident: bib0015 article-title: Soluble CD14 promotes LPS activation of CD14-deficient PNH monocytes and endothelial cells publication-title: J Lab Clin Med – volume: 84 start-page: 17 year: 1994 end-page: 25 ident: bib0030 article-title: Soluble CD14 (sCD14) levels in patients with multiple organ failure (MOF) publication-title: Res Commun Chem Pathol Pharmacol – volume: 249 start-page: 1431 year: 1990 end-page: 1433 ident: bib0010 article-title: CD14, a receptor for complex of lipopolysaccharide (LPS) and LPS binding protein publication-title: Science – volume: 16 start-page: 4173 year: 1988 ident: bib0005 article-title: Nucleotide sequence of the gene encoding the monocyte differentiation antigen, CD14 publication-title: Nucleic Acids Res – volume: 173 start-page: 661 year: 1996 end-page: 668 ident: bib0055 article-title: Function of soluble CD14 in serum from patients with septic shock publication-title: J Infect Dis – volume: 28 start-page: 2793 year: 2000 end-page: 2798 ident: bib0085 article-title: Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6 publication-title: Crit Care Med – volume: 341 start-page: 515 year: 1993 end-page: 518 ident: bib0065 article-title: High serum procalcitonin concentrations in patients with sepsis and infection publication-title: Lancet – volume: 147 start-page: 1567 year: 1991 end-page: 1574 ident: bib0075 article-title: Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes publication-title: J Immunol – volume: 155 start-page: 225 year: 1992 end-page: 232 ident: bib0020 article-title: An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids publication-title: J Immunol Methods – volume: 20 start-page: 864 year: 1992 end-page: 874 ident: bib0060 article-title: Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis publication-title: Crit Care Med – volume: 34 start-page: 307 year: 2003 end-page: 316 ident: bib0050 article-title: Recombinant bovine CD14 reduces severity of experimental publication-title: Vet Res – volume: 5 start-page: 283 year: 2000 end-page: 294 ident: bib0090 article-title: Immunological surrogate parameters in a prognostic model for multi-organ failure and death publication-title: Eur J Med Res – volume: 171 start-page: 639 year: 1995 end-page: 644 ident: bib0025 article-title: Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock publication-title: J Infect Dis – volume: 96 start-page: 15 year: 1994 end-page: 19 ident: bib0045 article-title: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus publication-title: Clin Exp Immunol – volume: 155 start-page: 937 year: 1997 end-page: 944 ident: bib0040 article-title: Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome publication-title: Am J Respir Crit Care Med – volume: 92 start-page: 2084 year: 1998 end-page: 2092 ident: bib0035 article-title: Elevated levels of serum-soluble CD14 in human immunodefiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events publication-title: Blood – volume: 25 start-page: 604 year: 1995 end-page: 610 ident: bib0070 article-title: Soluble lipopolysaccharide receptor (CD14) released via two different mechanisms from human monocytes and CD14 transfectants publication-title: Eur J Immunol – volume: 147 start-page: 1567 year: 1991 ident: 10.1007/s10156-005-0400-4_bib0075 article-title: Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes publication-title: J Immunol doi: 10.4049/jimmunol.147.5.1567 – volume: 16 start-page: 4173 year: 1988 ident: 10.1007/s10156-005-0400-4_bib0005 article-title: Nucleotide sequence of the gene encoding the monocyte differentiation antigen, CD14 publication-title: Nucleic Acids Res doi: 10.1093/nar/16.9.4173 – volume: 20 start-page: 864 year: 1992 ident: 10.1007/s10156-005-0400-4_bib0060 article-title: Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis publication-title: Crit Care Med doi: 10.1097/00003246-199206000-00025 – volume: 125 start-page: 662 year: 1995 ident: 10.1007/s10156-005-0400-4_bib0015 article-title: Soluble CD14 promotes LPS activation of CD14-deficient PNH monocytes and endothelial cells publication-title: J Lab Clin Med – volume: 249 start-page: 1431 year: 1990 ident: 10.1007/s10156-005-0400-4_bib0010 article-title: CD14, a receptor for complex of lipopolysaccharide (LPS) and LPS binding protein publication-title: Science doi: 10.1126/science.1698311 – volume: 155 start-page: 225 year: 1992 ident: 10.1007/s10156-005-0400-4_bib0020 article-title: An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids publication-title: J Immunol Methods doi: 10.1016/0022-1759(92)90289-6 – volume: 5 start-page: 283 year: 2000 ident: 10.1007/s10156-005-0400-4_bib0090 article-title: Immunological surrogate parameters in a prognostic model for multi-organ failure and death publication-title: Eur J Med Res – volume: 84 start-page: 17 year: 1994 ident: 10.1007/s10156-005-0400-4_bib0030 article-title: Soluble CD14 (sCD14) levels in patients with multiple organ failure (MOF) publication-title: Res Commun Chem Pathol Pharmacol – volume: 34 start-page: 307 year: 2003 ident: 10.1007/s10156-005-0400-4_bib0050 article-title: Recombinant bovine CD14 reduces severity of experimental Escherichia coli mastitis in mice publication-title: Vet Res doi: 10.1051/vetres:2003006 – volume: 30 start-page: 536 year: 2004 ident: 10.1007/s10156-005-0400-4_bib0080 article-title: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock publication-title: Intensive Care Med doi: 10.1007/s00134-004-2210-z – volume: 341 start-page: 515 year: 1993 ident: 10.1007/s10156-005-0400-4_bib0065 article-title: High serum procalcitonin concentrations in patients with sepsis and infection publication-title: Lancet doi: 10.1016/0140-6736(93)90277-N – volume: 28 start-page: 2793 year: 2000 ident: 10.1007/s10156-005-0400-4_bib0085 article-title: Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6 publication-title: Crit Care Med doi: 10.1097/00003246-200008000-00019 – volume: 171 start-page: 639 year: 1995 ident: 10.1007/s10156-005-0400-4_bib0025 article-title: Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock publication-title: J Infect Dis doi: 10.1093/infdis/171.3.639 – volume: 92 start-page: 2084 year: 1998 ident: 10.1007/s10156-005-0400-4_bib0035 article-title: Elevated levels of serum-soluble CD14 in human immunodefiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events publication-title: Blood doi: 10.1182/blood.V92.6.2084.418k26_2084_2092 – volume: 155 start-page: 937 year: 1997 ident: 10.1007/s10156-005-0400-4_bib0040 article-title: Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.155.3.9117029 – volume: 96 start-page: 15 year: 1994 ident: 10.1007/s10156-005-0400-4_bib0045 article-title: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.1994.tb06222.x – volume: 173 start-page: 661 year: 1996 ident: 10.1007/s10156-005-0400-4_bib0055 article-title: Function of soluble CD14 in serum from patients with septic shock publication-title: J Infect Dis doi: 10.1093/infdis/173.3.661 – volume: 25 start-page: 604 year: 1995 ident: 10.1007/s10156-005-0400-4_bib0070 article-title: Soluble lipopolysaccharide receptor (CD14) released via two different mechanisms from human monocytes and CD14 transfectants publication-title: Eur J Immunol doi: 10.1002/eji.1830250244 |
SSID | ssj0017588 |
Score | 2.2064605 |
Snippet | CD14, a high-affinity receptor for lipopolysaccharide (LPS), is a glycoprotein expressed on the surface membranes of monocytes/macrophages. We have identified... |
SourceID | proquest pubmed crossref nii elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 234 |
SubjectTerms | Aged Biomarkers - blood CD14 Diagnosis EIA Humans Immunoenzyme Techniques - methods Lipopolysaccharide Receptors - blood Male ROC Curve Sepsis Sepsis - diagnosis Severity of Illness Index SIRS Systemic Inflammatory Response Syndrome - diagnosis |
Title | Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1341321X05709764 https://dx.doi.org/10.1007/s10156-005-0400-4 https://cir.nii.ac.jp/crid/1571135650252594048 https://www.ncbi.nlm.nih.gov/pubmed/16258819 https://www.proquest.com/docview/17219170 https://www.proquest.com/docview/68741059 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swED7EydKl6Ltum5RDkaGIalGkJGoM3ATuKwjQBPBGkBQJCHBlI7IHL_ntubMkGx2cAl00CDyAOh7vvhPvPgJ8KkXwymZFVMpURcQoh3suqMgpT72OvJQ5NTj_usomt_L7NJ0ewLjvhaGyys73tz594627N6NOm6NFVY1-ExWZSPgUEUeMQVUO4CgRRYamfXT-7cfkanuYgJB40xGH4yMS6A832w46TGAiouMka47kvvA0qKtqPwjdBKPLZ_C0Q5HsvJ3oczjw9Qs4vW5pqNdn7GbXVdWcsVN2vSOoXr-Enxdbim82D8wwhNazNavKtnLIl4wM0s48G3_lkjUrSz9qmWlw6B8q57ljCHVZ4xdN1byC28uLm_Ek6m5ViJzMsiUmjIULQqQmdzZIZWQaQsGN8qmLrSlyxA8msWlQmUMVWUwXucEgL42TVoUsiNdwWM9r_xZYjmsbuC2LNCfiQFHYJBjBXTCypNb_IcS9MrXrKMfp5ouZ3pElk_416l-T_rUcwuetyKLl23hscNKvkO4bSdH1aYwGjwnJrdBflvYvsWM0AfwMevI051wgFkbEiPmjRDc4hI-9cWjcoXTsYmo_XzWakmxMiuP9IzKVU7VtMYQ3rVXtPh3TU4Wg7d3_Tfo9POmpZmP-AQ6Xdyt_jCBqaU9g8OWen3Rb5QFQTxFp |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9tAEB0BPbQX1EIpKQX2gDhUmHjjtb0-VikobQNCapByW-2udyVLwYlwcsilv52Z2E7UQ6jUiw_WrGSP5-ONd-YtwEUeeSdNkgW5iGVAjHLoc14GVjqadeS5SGnA-e4-GTyKn-N4vAP9dhaG2iqb2F_H9FW0bu50G212Z0XR_U1UZFGPjxFxhJhUxS68Eei-5J3Xf9Z9HpgeV4dPknRA4u3WZj0_h-VLQGScZMuB2Jacdsui2A5BV6no9j3sNxiSfasf8wPsuPIALh9qEurlFRttZqqqK3bJHjb01MtDGN6sCb7Z1DPNEFhPlqzI674hlzMyRzNxrP-dC1YtDP2mZbpC0Sdq5nlmCHRZ5WZVUX2Ex9ubUX8QNGcqBFYkyRzLxcz6KIp1ao0XUovY-4xr6WIbGp2liB50z8ReJhZVZLBY5BpTvNBWGOkTHx3BXjkt3TGwFL-s5ybP4pRoA6PM9LyOuPVa5DT434GwVaayDeE4nXsxURuqZNK_Qv0r0r8SHfi6XjKr2TZeE-61X0i1Y6QY-BTmgtcWifWiv-zsX8tO0QTwNejK45TzCJEw4kWsHgUGwQ6ct8ah0D9p00WXbrqoFJXYWBKH2yUSmVKvbdaBT7VVbV4di1OJkO3z_z30ObwdjO6Gavjj_tcJvGtJZ0P-Bfbmzwt3inBqbs5W7vICfJoSLQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+a+newly+identified+soluble+CD14+subtype+as+a+marker+for+sepsis&rft.jtitle=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.au=Yaegashi%2C+Yasunori&rft.au=Sato%2C+Nobuhiro&rft.au=Suzuki%2C+Yasushi&rft.au=Kojika%2C+Masahiro&rft.date=2005-10-01&rft.pub=Elsevier+Ltd&rft.issn=1341-321X&rft.volume=11&rft.issue=5&rft.spage=234&rft.epage=238&rft_id=info:doi/10.1007%2Fs10156-005-0400-4&rft.externalDocID=S1341321X05709764 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-321X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-321X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-321X&client=summon |